Article

Veltkamp, R, Korompoki, E, Harvey, KH, Harvey, ER, Fießler, C, Malzahn, U, Rücker, V, Montaner, J, Caso, V, Sibon, I, Ringleb, P, Halse, O, Hügen, K, Ullmann, S, Schuhmann, C, Todd, GP, Haas, K, Palà, E, Debette, S, Lachaize, M et al, D'Aoust, T, Enzinger, C, Ropele, S, Fandler-Höfler, S, Haidegger, M, Wang, Y, Wafa, HA, Cancelloni, V, Mosconi, MG, Lip, GYH, Lane, DA, Haefeli, WE, Foerster, KI, Wurmbach, VS, Nielsen, PB, Hajjar, K, Müller, P, Poli, S, Purrucker, J, Laible, M, D'Anna, L, Silva, Y, de Torres Chacon, R, Martínez-Sánchez, P, Boulanger, M, Norrving, B, Paré, G, Wachter, R, Ntaios, G, Wolfe, CDA, Heuschmann, PU, PRESTIGE-AF Consortium, and Lotto, R (2025) Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial. The Lancet, 405 (10482). pp. 927-936. ISSN 0140-6736